Eli Lilly Lifts 2026 Sales Outlook to $87 Billion on Strong Weight-Loss Drug Demand
Updated
Updated · Bloomberg · Aug 5
Eli Lilly Lifts 2026 Sales Outlook to $87 Billion on Strong Weight-Loss Drug Demand
3 articles · Updated · Bloomberg · Aug 5
Summary
Eli Lilly now expects 2026 sales of $85 billion to $87 billion, up from its prior $82 billion to $85 billion range after second-quarter results topped Wall Street estimates.
Strong demand for Lilly's weight-loss and diabetes medicines drove the increase, with the company saying second-quarter adjusted earnings and revenue both beat analyst forecasts.
Q2 revenue rose 48% to $23.0 billion in the earlier earnings release, led by sales volume for Mounjaro and Zepbound, while reported EPS increased 26% to $7.94.
The higher outlook extends Lilly's momentum in obesity and diabetes treatment markets, where blockbuster drug demand is increasingly shaping its growth trajectory.